Translation. Region: Russian Federation –
Source: Moscow Government – Moscow Government –
An important disclaimer is at the bottom of this article.
The Moscow Endocrine Plant (FSUE Endopharm) has completed a large-scale renovation of its laboratory complex, introducing advanced quality control and drug development methods. This was announced by the Moscow Government Minister and Head of the Department of Investment and Industrial Policy. Anatoly Garbuzov.
"The capital occupies a leading position in Russia's pharmaceutical industry. Companies are actively developing scientific and industrial activities and modernizing their facilities. For example, the Moscow Endocrine Plant has completed the reconstruction of a modern 1,250-square-meter laboratory center, which will employ over 100 specialists—laboratory technicians, chemists, and engineers. Their key task is to ensure multi-stage quality control at all stages of production. They will also develop new technologies, improve existing methods, and create promising solutions for the domestic market," said Anatoly Garbuzov.
Technology development and pharmaceutical research
The solutions and equipment of the reconstructed laboratory complex allow for the creation and implementation of new technological solutions, formulation improvements, and experimental and research work on the selection of alternative active pharmaceutical ingredients (APIs), excipients, and packaging materials.
Over 700 units of equipment are installed on the site, including chromatographs for the separation and quantitative analysis of multicomponent mixtures, a flow-through disperser and high-pressure homogenizer designed to create stable micro- and nanoemulsions (used in the production of anesthetic and anaesthetic drugs), and other devices.
The complex features clear zoning, including the creation of clean rooms for aseptic work. Particular attention is paid to environmental aspects and zero environmental impact through a modern multi-level filtration and waste disposal system.
"The opening of a laboratory complex at the production site is part of Endopharm's strategy to reconstruct and upgrade its key facilities. The company will be able to conduct over 22,000 tests annually at the modernized facilities. The complex's capacity will ultimately facilitate technology transfer to the Lefortovo research and production cluster, scheduled to launch in the second half of 2026, and will also facilitate the scaling of the production of import-substituting drugs in liquid dosage forms—solutions, drops, and emulsions," noted Mikhail Fonarev, the company's CEO.
The plant was founded in 1943 and was one of the first in Russia to implement international standards for ensuring quality control of medicines at every stage of production.
Today, the full-cycle enterprise produces over 160 domestically produced import-substituting medications used in ophthalmology, cardiology, gynecology, oncology, palliative care, psychoneurology, and anesthesiology, as well as anti-inflammatory and metabolic drugs. Over 80 percent of these medications are included in the VED (vital and essential drugs) list.
As part of the implementation of the Russian Federation's healthcare development strategy through 2030, approved by decree of Russian President Vladimir Putin, the flagship line of centrally acting analgesics is being expanded, and new dosage forms are being introduced that meet the current needs of the medical community.
Three stages of modernization
The program for the modernization and technical re-equipment of key capacities of FSUE Endopharm is being implemented in three stages.
As part of the first project in 2023, a comprehensive reconstruction of the scientific laboratory complex of the Lefortovo branch (Laboratornaya Street, Building 12, Building 2) with a total area of 6.2 thousand square meters was completed.
During the second phase, the laboratory complex at the production site (25 Novokhokhlovskaya Street, Building 1) was commissioned in February 2026. Construction is also underway at the Lefortovo branch, a 13,900-square-meter facility planned to house five workshops comprising seven high-tech production lines, with the potential to create over 500 jobs.
The bulk of the new research and production complex's output will be medications for the treatment of socially significant diseases—malignant tumors and circulatory diseases, in particular, drugs used to stabilize blood pressure, treat arrhythmia, tachycardia, myocardial infarction, and other cardiac conditions. Furthermore, plans call for expanded production of anesthesiology products, as well as medications used in palliative care, neurology, psychiatry, and other clinical areas—many of these medications have not previously been produced in Russia.
The third phase is planned for completion by 2029. It is expected to see the completion of two laboratory, administrative, and warehouse complexes (LASK) at the production site, covering 15,200 square meters, and at the Lefortovo branch, covering 5,500 square meters (23 Entuziastov Highway). Once operational, the complexes will create 300 jobs for the city.
The capital has created a comprehensive support mechanism for the industry: from tax incentives to infrastructure solutions—more than 20 financial and non-financial instruments. In 2021, the city signed a contract with the plant guaranteeing sales in the pharmaceutical sector. Deliveries began in 2023. Under the contract, the company supplies the capital with antiglaucoma, antibacterial, and analgesic medications, as well as antidepressants and antipsychotics.
Get the latest news quickly on official Moscow messaging channels. MAX And Telegram.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.
